Welcome to our dedicated page for 60 Degrees Pharm news (Ticker: SXTPW), a resource for investors and traders seeking the latest updates and insights on 60 Degrees Pharm stock.
60 Degrees Pharmaceuticals develops and commercializes medicines for vector-borne disease, with news centered on ARAKODA® (tafenoquine), its FDA-approved malaria prophylaxis product, and related tafenoquine development work. Company updates also cover access and marketing partnerships for ARAKODA, annual product revenue reporting, capital actions, and Nasdaq listing-related corporate measures.
Recurring development news includes studies involving tafenoquine for babesiosis, where the drug is not FDA-approved, and regulatory and licensing activity tied to Australian Chestnut Extract, castanospermine, celgosivir-related science, and non-prescription botanical product plans.
Summary not available.